A New Dawn in Cancer's Demise? mRNA Therapy Enters Human Trials

The first U.S. patient has received a dose of mRNA-4106, Moderna's pioneering pan-tumor antigen therapy candidate, in a Phase 1 trial.
Conducted at the START Center for Cancer Research, the trial targets advanced or metastatic solid tumors using cutting-edge mRNA technology.
This multivalent approach aims to create a broadly effective treatment against diverse cancers, potentially revolutionizing immunotherapy.

In a landmark moment for oncology, the first U.S. patient has been dosed in Moderna's Phase 1 clinical trial for mRNA-4106, a revolutionary pan-tumor antigen therapy candidate. This pivotal step, taken at the START Center for Cancer Research, offers a new beacon of hope for patients battling advanced or metastatic solid tumors^{1, 2}.

"mRNA represents a bold new frontier in cancer immunotherapy," declared Dr. Amita Patnaik, who administered the first dose at START San Antonio. "We're proud to provide our patients access to this innovative treatment as part of a first-in-human trial."

The trial (ClinicalTrials.gov identifier: NCT06880549) will scrutinize the safety and initial efficacy of mRNA-4106, both alone and combined with checkpoint inhibitors¹. Unlike therapies targeting single markers, mRNA-4106 employs a multivalent strategy, encoding multiple antigens common across various tumor types like lung, breast, and pancreatic cancers. This "pan-tumor" design aims to unleash the immune system against cancer on several fronts simultaneously, potentially transforming treatment for a wide array of patients^{1, 8}.

"This milestone reflects the core of who we are at START - accelerating the next generation of cancer therapies by bringing them directly to patients in the communities where they live," stated Nick Slack, Chairman and CEO of START².

Moderna's foray into oncology with mRNA technology, building on its vaccine successes, signifies a bold shift. "With mRNA-4106, we sought to design an inclusive therapy that encodes for antigens commonly shared across patients and tumor types," said Dr. , Executive Vice President of Research at Moderna.

This trial underscores START's mission of "Hope Through Access," bringing transformative therapies from the lab to the community, and potentially heralding a new, more inclusive era in the fight against cancer^{1, 2, 8}.

A New Dawn in Cancer's Demise? mRNA Therapy Enters Human Trials

References

Stay Updated!